Showing 1811-1820 of 2526 results for "".
- Aviceda Announces its Glycomimetic Nanoparticle Candidate AVD-104 Demonstrates Clinical Safety in the Treatment of GAhttps://modernod.com/news/aviceda-announces-its-glycomimetic-nanoparticle-candidate-avd-104-demonstrates-clinical-safety-in-the-treatment-of-ga/2481886/Aviceda Therapeutics announced the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the Euretina congress held in Amsterdam. The phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-
- Alcon Launches TOTAL30 Multifocal Contact Lenses for Patients with Presbyopiahttps://modernod.com/news/alcon-launches-total30-multifocal-contact-lenses-for-patients-with-presbyopia/2481879/Alcon announced the global launch of TOTAL30 Multifocal, the first and only monthly water gradient multifocal contact lens, according to Alcon. The lenses have begun to roll out in the United States and in select international markets. Many lens wearers stop wearing contact le
- Optometry Giving Sight Sets $500,000 Fundraising Goal for the 2023 World Sight Day Challengehttps://modernod.com/news/optometry-giving-sight-sets-500000-fundraising-goal-for-the-2023-world-sight-day-challenge/2481868/Optometry Giving Sight (OGS) has announced a $500,000 fundraising goal for its 2023 World Sight Day Challenge. Donations will fuel the organization’s efforts to help eradicate uncorrected refractive error through the growth and expansion of optometry around the world. The the
- Business Executive Alex Gorsky Joins Neurotech’s Board as Lead Directorhttps://modernod.com/news/business-executive-alex-gorsky-joins-neurotechs-board-as-lead-director/2481827/Neurotech Pharmaceuticals announced that Alex Gorsky has been elected to Neurotech’s board as Lead Director. Mr. Gorsky is the former Chairman and CEO of Johnson & Johnson. Under Mr. Gorsky’s leadership, Johnson & Johnson grew to become one of world’s larg
- MSU Researchers Discover Link Between Cholesterol and Diabetic Retinopathyhttps://modernod.com/news/msu-researchers-discover-link-between-cholesterol-and-diabetic-retinopathy/2481822/Research led by Michigan State and other universities found that diabetes, age-related health conditions, and other metabolic disorders can lead to a buildup of cholesterol in the retina. This tends to crystalize and contribute to the development of diabetic retinopathy. Cryst
- NovaBay Pharmaceuticals Enters Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allografthttps://modernod.com/news/novabay-pharmaceuticals-enters-agreement-with-biostem-technologies-to-commercialize-amniotic-tissue-allograft-as-avenova-allograft/2481821/NovaBay Pharmaceuticals and BioStem Technologies announced an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces. Fi
- Award-Winning Actress, Dancer and Director Debbie Allen Joins Prevent Blindness and Regeneron to Raise Awareness of Serious Retinal Diseaseshttps://modernod.com/news/award-winning-actress-dancer-and-director-debbie-allen-joins-prevent-blindness-and-regeneron-to-raise-awareness-of-serious-retinal-diseases/2481818/Award-winning actress, dancer and director Debbie Allen is partnering with Prevent Blindness and Regeneron to launch the 'Gr8 Eye Movement,' a new disease awareness campaign that aims to address gaps in how people understand the risk of developing certain serious retinal di
- UC Irvine Researchers Discover a Nanobody that May Lead to Treatment for Retinitis Pigmentosahttps://modernod.com/news/uc-irvine-researchers-discover-a-nanobody-which-may-lead-to-treatment-for-retinitis-pigmentosa/2481805/A team of scientists from the University of California, Irvine, believe they have discovered a special antibody which may lead to a treatment for retinitis pigmentosa. The study,
- The FDA Does Not Approve Outlook Therapeutics' BLA for Lytenava for the Treatment of Wet AMDhttps://modernod.com/news/the-fda-does-not-approve-outlook-therapeuticss-bla-for-lytenava-for-the-treatment-of-wet-amd/2481800/Outlook Therapeutics announced the FDA has issued a complete response letter (CRL) to the company’s BLA for ONS-5010 (Lytenava), an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its s
- American Academy of Optometry Announces the 2023 Garlan W. Clay Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-the-2023-garlan-w-clay-award-recipients/2481798/The American Academy of Optometry has announced the recipients of the 2023 Garland W. Clay award: From the College of Optometry, The Ohio State University, Columbus, Ohio: Donald O. Mutti, OD, PhD, FAAO Loraine T. Sinnott, PhD G. Lynn Mitchel